UroGen Pharma Ltd. (URGN)

Market Cap	1.11B
Revenue (ttm)	96.52M
Net Income (ttm)	-164.64M
Shares Out	46.81M
EPS (ttm)	-3.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,190,409
Open	23.83
Previous Close	23.76
Day's Range	23.36 - 24.12
52-Week Range	3.42 - 25.19
Beta	1.26
Analysts	Strong Buy
Price Target	28.50 (+20.25%)
Earnings Date	Nov 6, 2025

About URGN

UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscl...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 4, 2017
• Employees: 235
• Stock Exchange: NASDAQ
• Ticker Symbol: URGN
• Website: https://www.urogen.com

Financial Performance

In 2024, UroGen Pharma's revenue was $90.40 million, an increase of 9.29% compared to the previous year's $82.71 million. Losses were -$126.87 million, 24.1% more than in 2023.

Analyst Summary

According to 8 analysts, the average rating for URGN stock is "Strong Buy." The 12-month stock price target is $28.5, which is an increase of 20.25% from the latest price.

Price Target

$28.5

(20.25% upside)

Analyst Consensus: Strong Buy